


ANNUAL REPORT

FY2023



COPD
FOUNDATION®

LEADERSHIP MESSAGE

Dear Friends and Supporters,

As we reflect on this past year, we're proud to share a time of transformation, growth, and deepened impact at the COPD Foundation. Together, we continued advancing our mission to improve the lives of those affected by COPD, bronchiectasis, and NTM lung disease with renewed energy and a clear vision for the future.

December 2022 marked an important leadership transition for the Foundation as Jean Wright, M.D., MBA, joined the organization as Chief Executive Officer. Since then, the Foundation has made significant strides in broadening its reach and deepening its support for the community through Jean's vision, extensive experience in health care innovation, and commitment to patient-centered leadership.

We expanded our educational efforts with the release of the All About Bronchiectasis booklet in both English and Spanish, ensuring more individuals and families have access to essential information in the language they trust. On World Bronchiectasis Day, we united with two new global partners and reached an incredible 2.2 million people, nearly triple our reach from the previous year.

July marked the successful completion of the CIRCLES program focused on improving COPD management for people in rural areas, as well as assisting in patient-provider communication. Participants reported meaningful improvements in self-management, symptom control, and communication with their health care teams. We also reintroduced the popular "Coffee Break" virtual meet-ups in September, creating a space for connection, support, and shared experiences.

In October, we invited our community to engage in movement and wellness through our Lace Up for Lungs campaign and the Get Active Your Way for 31 Days challenge. These two efforts are designed to inspire better lung health through physical activity and personal empowerment.

We were thrilled to see our COPD360social community surpass 56,000 members from 151 countries, reflecting the truly global nature of our community. And through our IMPACT advocacy program, 86 volunteer advocates from 34 states participated in 145 virtual meetings with lawmakers, the highest level of engagement in the program's history.

This year's progress is a testament to the power of collaboration among patients, caregivers, clinicians, researchers, and advocates. Thank you for being part of this journey and for helping us shape a healthier, more hopeful future for people affected by chronic lung disease.

Until we have a cure,

The block contains two handwritten signatures in black ink. The signature on the left is "Jean Wright MD" and the signature on the right is "James Wright".



Jean Wright, M.D., MBA
Chief Executive Officer



James D. Crapo, M.D.
Board Chair

MISSION

OUR MISSION

The COPD Foundation's mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease.

VISION

OUR VISION

As the global leaders in the fight to cure COPD, bronchiectasis, and NTM lung disease, our vision is a world where everyone has the awareness, resources, and opportunity to breathe well.

BOARD OF DIRECTORS

Chair: James D. Crapo, M.D.

Vice-chair & Treasurer: Wayne E. "Chip" Withers

MEMBERS

Richard Casaburi, M.D., Ph.D.

Valerie Chang, J.D.

Stew Cogan, Esq.

Mark Dransfield, M.D.

Leonard Fromer, M.D.

Donald Gray

MeiLan K. Han, M.D., M.S.

Mike Rogers

Risa Stack, Ph.D.

Byron M. Thomashow, M.D.

Herbert Yardley

EMERITUS MEMBERS

Grace Anne Dorney Koppel, Esq., M.A., J.D.

Gerard Turino, M.D.

Robert Wise, M.D.

MEDICAL AND SCIENTIFIC ADVISORY COMMITTEE

Mark Dransfield, M.D., Chair
Jill Ohar, M.D., Vice-chair
Alvar Agusti, M.D., Ph.D., FRCPE
Timothy R. Aksamit, M.D.
Antonio Anzueto, M.D.
David Au, M.D., M.S.
R. Graham Barr, M.D., DrPH
Surya Bhatt, M.D.
Richard Casaburi, M.D., Ph.D.
Bartolome Celli, M.D.
James Chalmers, M.D.
James Crapo, M.D.
Gerard Criner, M.D., FACP, FACCP
James Donohue, M.D.
Brad Drummond, M.D., MHS
Marilyn Foreman, M.D.
Karin Hoth, Ph.D., ABPP
Min Joo, M.D., MPH, FCCP, ATSF
Ravi Kalhan, M.D., M.S.
Jerry Krishnan, M.D., Ph.D.
Peter Lindenauer, M.D., MSc

Barry Make, M.D.
David Mannino, M.D.
Fernando Martinez, M.D.
Mark Metersky, M.D., FCCP
Richard Mularski, M.D., MSHS, MCR, FCCP
Nirupama Putcha, M.D.
Wilson Quezada, M.D.
Stephen Rennard, M.D., RRT, FAARC
Jean Rommes, Ph.D.
Robert A. Sandhaus, M.D., Ph.D.
Frank Sciurba, M.D., FCCP
Paul Simonelli, M.D., Ph.D.
Lewis J. Smith, M.D.
Rob Stockley, M.D.
Ruth Tal-Singer, Ph.D.
Byron Thomashow, M.D.
Gerard Turino, M.D.
George Washko, M.D.
Robert (Bob) Wise, M.D.
Barbara Yawn, M.D., MSc

COPD360 COMMUNITY ENGAGEMENT COMMITTEE

Kenneth Benson
Goldia Brown
Valerie Chang
Janice Cotton
Karen Erickson
Caroline Gainer
Louise Hobden
Scott Hobden
David Reynolds
Jean Rommes
John Torrence



FINANCIALS

As a 501(c)(3) organization, the COPD Foundation's ability to advance our mission and drive meaningful impact is made possible by the generosity of our donors and corporate partners (see page 7), and funding from industry, foundations, and government grants.

- Total revenue: \$8,074,231
- Contributions & Other: \$7,465,783
- Total expenses: \$9,649,179
- Programmatic expenses: \$6,857,246

ASSETS

Cash & cash equivalents	\$3,320,835
Marketable securities	\$4,042,892
Accounts receivable	\$735,281
Prepaid expenses	\$409,885
Property and equipment, net	\$17,609
Marketable securities, long term	<u>\$385,208</u>
Total Assets	\$8,911,710

For complete information, please refer to the independently audited financial statements of the COPD Foundation at copdfoundation.org.

DEVELOPMENT

Dear Friends,

On behalf of the entire COPD Foundation community, we extend our deepest gratitude for your generosity, commitment, and unwavering support.

This past year has proven to be a great year of progress and achievements for the COPD Foundation. Your contribution has bolstered our mission to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease.

The impact made possible through your support is a constant inspiration. Because of you, we were able to expand access to education and support services, accelerate vital research, and advocate for better policies and treatments.

Your belief in our mission fuels everything we do. It enables us to keep pushing forward—toward earlier diagnoses, improved care, and ultimately, a cure. We thank you for being champions of hope, partners in progress, and part of a growing movement that is changing the future of lung health.

COPD Foundation Board of Directors and COPD Foundation Team



CORPORATE

Thank You

COPD Foundation Corporate Support Program Partners

GSK, plc.

AstraZeneca

Insmmed Incorporated

Pfizer

Sanofi-Regeneron

Takeda

Theravance

Viatrix

Verona Pharma

Pneumagen

Wellinks

Zambon SpA

Bronchiectasis and NTM 360 Supporters

AN2 Therapeutics

AstraZeneca

Boehringer Ingelheim

Electromed

GlaxoSmithKline

Insmmed Incorporated

NTM Info & Research

Oregon Health and Science University

Peerview Institute for Medical Education

Zambon

